Startups
Leveraging genetically validated targets to build next generation treatments for rare neuromuscular diseases We are combining best in class target-optimized ASO and gapmer therapeutics with two novel delivery technologies. Our ASO+delivery combinations can trigger gene ‘knock up’ and ‘knock down’. Our technologies are differentiated by improved targeting, penetration, and efficacy, in addition to reduced toxicity […]